CADILA HEALTHCARE LTD. - 532321 - Board Meeting Intimation for Notice Of Board Meeting
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2021 ,inter alia, to consider and approve Audited Financial Results for the year ended on March 31, 2021 and recommendation of final dividend for the financial year 2020-2021.
Covid-19 drugs and vaccines to drive Cadila Healthcare's prospects
The company received emergency use approval for Pegylated Interferon alpha-2b, Virafin' in treating moderate COVID-19 infection in adults. Priced at 11,995/dose, it is said to cut the need for oxygen supply CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Notice of Extra Ordinary General Meeting CADILA HEALTHCARE LTD. - 532321 - Extra Ordinary General Meeting
Extra Ordinary General Meeting of the members of the Company
COVID-19 Vaccine | Cadila Health says it is on track' for May submission of vaccine to DCGI
Cadila will file for emergency use authorisation after it has submitted its vaccine to the Drugs Controller General of India
Zydus Cadila to sell India animal health business for Rs 2,921 crore
We are sure that ZAHL will continue to grow and strengthen its position, said Pankaj Patel Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst / Investors call on May 12, 2021 Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila entity to sell its India focused Animal Health Business to Multiples Alternate Asset Management led consortium CADILA HEALTHCARE LTD. - 532321 - Announcement Under Regulation 30 Of SEBI LODR
Announcement under regulation 30 of SEBI LODR
Cadila Healthcare eyes approval for Covid vaccine by June in India: Report
Cadila Healthcare plans to submit trial data for its Covid-19 vaccine by end of May and is looking for an approval in June